Next Article in Journal
Report from the Scientific Poster Session at the 15th Annual Cardiometabolic Health Congress Live Online, USA, 21–24 October 2020
Previous Article in Journal
Reliability of the Soleus H-Reflex in Different Sitting Postures
Article

Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer

1
Research Institute i+12, University Hospital 12 de Octubre, Faculty of Medicine, Complutense University, 28041 Madrid, Spain
2
Endocrinology Service, University Hospital 12 de Octubre, 28041 Madrid, Spain
3
La Luz Hospital, 28003 Madrid, Spain
4
Epidemiology Unit, Research Institute i+12, University Hospital 12 de Octubre, 28041 Madrid, Spain
5
Centro de Salud Goya, 28009 Madrid, Spain
*
Author to whom correspondence should be addressed.
Med. Sci. 2020, 8(4), 49; https://doi.org/10.3390/medsci8040049
Received: 20 October 2020 / Revised: 18 November 2020 / Accepted: 23 November 2020 / Published: 1 December 2020
(This article belongs to the Section Endocrinology and Metabolic Diseases)
The association of low levels of 25 hydroxyvitamin D (25OHD) with papillary thyroid cancer (PTC) is being studied, as to whether it is a risk factor or as a coincidental one. This study aimed to evaluate serum levels of deficiency, insufficiency, and sufficiency of 25OHD in PTC and its relationship with the trabecular bone score (TBS) and bone mineral density (BMD). This study includes 134 postmenopausal women with PTC, followed for 10 years. BMD was measured with DXA Hologic QDR 4500, and TBS with Med-Imaps iNsight2.0 Software. Mean serum 25OHD was 23.09 ± 7.9 ng/mL and deficiency, insufficiency, and sufficiency levels were 15.64 ± 2.9, 25.27 ± 2.7, and 34.7 ng/mL, respectively. Parathyroid hormone (PTH) and bone alkaline phosphatase (BAP) were higher in deficiency (57.65 ± 22.6 ng/mL; 29.5 ± 14 U/L) and in insufficiency (45.88 ± 19.8 ng/mL; 23.47 ± 8.8 U/L) compared with sufficiency of 25OHD (47.13 ± 16 and 22.14± 9.7 ng/mL) (p = 0.062 and p = 0.0440, respectively). TBS was lower in patients with 25OHD < 20 ng/mL (1.24 ± 0.13) compared with between 20–29 (1.27 ± 0.13, p < 0.05) and 30 ng/mL (1.31 ± 0.11, p < 0.01). We found low TBS in patients with PTC and long-term follow-up associated with low serum 25OHD levels, not associated with cancer stage, or accumulative iodine radioactive dose. Low 25OHD associated with deleterious bone quality in patients with PTC should be restored for the prevention of fractures. View Full-Text
Keywords: 25 hydroxyvitamin D; differentiated thyroid cancer; bone mineral density; trabecular bone structure; TSH suppression therapy 25 hydroxyvitamin D; differentiated thyroid cancer; bone mineral density; trabecular bone structure; TSH suppression therapy
Show Figures

Figure 1

MDPI and ACS Style

Hawkins Carranza, F.; Guadalix Iglesias, S.; De Mingo Dominguez, M.L.; Allo Miguel, G.; Arroba, C.M.-A.; Alvares, B.L.; Martínez Diaz-Guerra, G. Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer. Med. Sci. 2020, 8, 49. https://doi.org/10.3390/medsci8040049

AMA Style

Hawkins Carranza F, Guadalix Iglesias S, De Mingo Dominguez ML, Allo Miguel G, Arroba CM-A, Alvares BL, Martínez Diaz-Guerra G. Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer. Medical Sciences. 2020; 8(4):49. https://doi.org/10.3390/medsci8040049

Chicago/Turabian Style

Hawkins Carranza, Federico, Sonsoles Guadalix Iglesias, María L. De Mingo Dominguez, Gonzalo Allo Miguel, Cristina M.-A. Arroba, Begoña L. Alvares, and Guillermo Martínez Diaz-Guerra. 2020. "Association of Low Serum 25OHD Levels with Abnormal Bone Microarchitecture in Well-Differentiated Thyroid Cancer" Medical Sciences 8, no. 4: 49. https://doi.org/10.3390/medsci8040049

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop